MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...
Its offerings include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI. On May 22, ESPR and Daiichi Sankyo Europe GmbH announced the ...
Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO ® (pexidartinib) at the Connective Tissue Oncology Society (#CTOS2024) 2024 Annual ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Investor's Business Daily on MSN1d
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback